About RQX Pharmaceuticals
RQX Pharmaceuticals is a Healthcare company based in San Diego (United States) founded in 2010, and was acquired by Genentech in February 2013. Novel antibiotics for community and hospital infections are developed. RQX Pharmaceuticals has raised $1.19 million across 1 funding round from investors including Genentech and Avalon Ventures. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
RQx Pharmaceuticals develops broad-spectrum antibiotics. Focused on a novel molecular target for which no antibiotic has been developed. Additionally, the company has generated proprietary molecules based on a novel chemical scaffold. The companys initial products focussed on community and hospital-associated infections, including those from gram-negative bacteria. Was founded based on discoveries in Floyd Romesbergs lab at The Scripps Research Institute in La Jolla, CA. Genentech signed 111 million deal with the company to discover and develop compounds against an undisclosed target. RQx is a portfolio company of Avalon Ventures and also received investments from COI Pharmaceuticals.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website rqxpharmaceuticals.com
- Social LinkedIn
- Acquired by Genentech (Feb 2013)
Funding Insights of RQX Pharmaceuticals
RQX Pharmaceuticals has successfully raised a total of $1.19M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.19 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.19M
- Total Rounds 1
- Last Round Seed — $1.19M
- First Round $1.19M
(Feb 2011)
- Investors Count 1
All 1 funding rounds of RQX Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2011 | $1.19M | Seed | – | Avalon Ventures | – |
2 investors in total: 2 institutional.
Investors in RQX Pharmaceuticals
RQX Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech and Avalon Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage venture capital is provided to US companies. | avalon-ventures.com | Cambridge, United States | ||
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1976 | gene.com | San Francisco, United States |
Investor details for RQX Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of RQX Pharmaceuticals
3 dated milestones of RQX Pharmaceuticals across 3 years, from founding to its latest funding, stage changes and deals.
- Founded RQX Pharmaceuticals is founded.
- Funding First funding round of $1.2M.
- Exit Acquired by Genentech.
Competitors of RQX Pharmaceuticals
RQX Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. |
Detailed competitors of RQX Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as RQX Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about RQX Pharmaceuticals
RQX Pharmaceuticals was founded in 2010 and raised its 1st funding round 1 year after it was founded.
RQX Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
RQX Pharmaceuticals is a funded company, having raised a total of $1.19M across 1 funding round to date. The company's 1st funding round was a Seed of $1.19M, raised on Feb 2011.
RQx Pharmaceuticals develops broad-spectrum antibiotics. Focused on a novel molecular target for which no antibiotic has been developed. Additionally, the company has generated proprietary molecules based on a novel chemical scaffold. The companys initial products focussed on community and hospital-associated infections, including those from gram-negative bacteria. Was founded based on discoveries in Floyd Romesbergs lab at The Scripps Research Institute in La Jolla, CA. Genentech signed 111 million deal with the company to discover and develop compounds against an undisclosed target. RQx is a portfolio company of Avalon Ventures and also received investments from COI Pharmaceuticals.
RQX Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
RQX Pharmaceuticals has 2 investors. Key investors include Genentech, and Avalon Ventures.
Yes. RQX Pharmaceuticals was acquired by Genentech in February 2013.